Summary of Study ST002958

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001840. The data can be accessed directly via it's Project DOI: 10.21228/M8W13F This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Study ID	ST002958
Study Title	Lipidomic analysis of demyelination and remyelination in the Plp1-iCKO-Myrf mouse model of demyelination
Study Summary	In this study, we obtained a longitudinal lipidomic profile of the brain, spinal cord, and serum using a genetic mouse model of demyelination, known as Plp1-iCKO-Myrf mice. This model has distinct phases of demyelination and remyelination over the course of 24 weeks, in which loss of motor function peaks during demyelination.
Institute	University of Kansas
Last Name	Hartley
First Name	Meredith
Address	2030 Becker Drive, Room 220F
Email	hartley@ku.edu
Phone	7858641782
Submit Date	2023-10-31
Raw Data Available	Yes
Raw Data File Type(s)	mzXML
Analysis Type Detail	LC-MS
Release Date	2023-11-17
Release Version	1

Select appropriate tab below to view additional metadata details:

Treatment:

Treatment ID:	TR003080
Treatment Summary:	Plp1-iCKO-Myrf mice were randomly assigned into the control or Sob-AM2 treatment groups. Both Cre negative mice, which do not lose Myrf and undergo demyelination, and Cre positive mice, which do undergo demyelination, were used in all experiments. The control group received control chow (Envigo Teklad 2016 diet) and the Sob-AM2 treatment group received chow containing 420 µg/kg chow of Sob-AM2 (nominal daily dose of 84 µg/kg body weight) starting 2 weeks after tamoxifen injections. Mice on control chow were euthanized at 4 timepoints: 6, 12, 18, and 24 weeks post-tamoxifen injections. Mice treated with Sob-AM2 were euthanized at 12 and 18 weeks post-tamoxifen.

Treatment ID:

TR003080

Treatment Summary:

Plp1-iCKO-Myrf mice were randomly assigned into the control or Sob-AM2 treatment groups. Both Cre negative mice, which do not lose Myrf and undergo demyelination, and Cre positive mice, which do undergo demyelination, were used in all experiments. The control group received control chow (Envigo Teklad 2016 diet) and the Sob-AM2 treatment group received chow containing 420 µg/kg chow of Sob-AM2 (nominal daily dose of 84 µg/kg body weight) starting 2 weeks after tamoxifen injections. Mice on control chow were euthanized at 4 timepoints: 6, 12, 18, and 24 weeks post-tamoxifen injections. Mice treated with Sob-AM2 were euthanized at 12 and 18 weeks post-tamoxifen.